<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients treated with epidermal growth factor receptor inhibitors (EGFRIs) may develop dermatologic adverse drug reactions (ADRs) that may affect patients' quality-of-life, require medical care, and may lead to substantial costs </plain></SENT>
<SENT sid="1" pm="."><plain>This study assessed the economic burden of dermatologic ADRs in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> (<z:chebi fb="170" ids="36856">HNC</z:chebi>), and <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Adult patients with ≥1 diagnosis for the study <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> initiated on EGFRIs indicated for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, <z:chebi fb="170" ids="36856">HNC</z:chebi>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> were selected from a large commercial database (MarketScan Commercial Database [2000-2010]; Thomas Reuters, New York, NY) </plain></SENT>
<SENT sid="3" pm="."><plain>For each <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> type, patients were classified into two mutually exclusive cohorts: 'ADR' (patients with ≥1 ADR following EGFRI initiation) and 'ADR-free' (patients without any ADR) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were observed from the index date up to the end of continuous healthcare plan enrollment or 90 days after EGFRI discontinuation, whichever occurred first </plain></SENT>
<SENT sid="5" pm="."><plain>For each <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> group, the proportion of patients and the incidence rate (IR) of experiencing ≥1 dermatologic ADR were reported </plain></SENT>
<SENT sid="6" pm="."><plain>Incidence rate ratios for healthcare resource utilization and monthly incremental costs (2010 USD) were estimated using Poisson regression and generalized linear or two-part models, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Overall, the proportion of patients with ≥1 ADR ranged between 20.5-36.4% across <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> groups (IR ranged between 44.2-57.4 per 100 patient-years) </plain></SENT>
<SENT sid="8" pm="."><plain>After adjusting for confounders, in each <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> group, ADR patients had higher incidence of healthcare resource utilization, generally driven by higher incidence of emergency room visits and incurred incremental total monthly healthcare costs that ranged between $2284-$3210 across <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> groups </plain></SENT>
<SENT sid="9" pm="."><plain>LIMITATIONS: There was no clinical measure of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> staging and ADR severity in the database </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Results suggest that patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>, and <z:chebi fb="170" ids="36856">HNC</z:chebi>, who may benefit from EGFRI therapies, may also incur a substantial economic burden that is associated with dermatologic ADRs </plain></SENT>
</text></document>